Stock Price Prediction

LLYVA stock is currently trading near $728, showing strong support around $722, as highlighted by technical analysts. The recent dip was driven by lower-than-expected sales guidance for 2024, but the company still projects 32% revenue growth in 2025, supported by its blockbuster drugs like Mounjaro and Zepbound. Bulls view this as a buying opportunity, expecting a rebound above $750 in the near term due to robust fundamentals and growth prospects.

LLYVA stock is currently trading with a bullish pre-market gain of over 6%, but bears may argue that the recent rally lacks strong fundamental support. The stock's upward movement appears driven by broader market optimism rather than company-specific catalysts, making it vulnerable to profit-taking. A potential resistance level near $50 could limit further upside unless supported by stronger earnings or strategic developments.